Conclusion: We demonstrate that CAP therapy could be effectively and safely applied in cfLVAD patients with SDI. Using CAP 70% of our cases with SDI were prevented from ADI. Future studies have to show if ambu- lant CAP therapy of superficial cfLVAD wound infections has the poten- tial to prevent progression of infection or to avoid SDI infection at all. (1217) A Single Institutional Experience with 66 Children Supported with the Berlin Heart Ventricular Assist Device over 16 Years: Comparison of Patients with Congenital versus Acquired Heart Disease M.S. Bleiweis, Y.J. Stukov, J. Philip, G.J. Peek and J.P. Jacobs. Congenital Heart Center, University of Florida, Gainesville, FL. Purpose: To evaluate outcomes in children supported with the Berlin Heart VAD, comparing those with congenital heart disease (CHD) to those with acquired heart disease (AHD). Methods: We reviewed all 66 patients supported with the Berlin Heart VAD at our institution. Primary outcome was mortality. Kaplan-Meier methods and log-rank tests were used to assess group differences in long- term survival. Results: 31 AHD patients (Age [years]: mean+/-SD = 4.3+/-4.8, median = 1.9, range = 25 days-16 years; Weight [kilograms]: mean +/-SD = 16.7+/-16.16, median = 11, range = 3.11-60), including 28 BiVAD and 3 LVAD only. In patients with AHD, duration of VAD support [days]: mean = 99.2, median = 93, range = 2-315. Of 31 patients with AHD, 24 underwent heart transplantation, 4 weaned off VAD, 2 died on VAD, and 1 is still on VAD. 35 CHD patients (Age [years]: mean+/-SD = 2.4+/-3.8, median = 0.18, range = 4 days-13 years; Weight [kilograms]: mean +/-SD = 9.13+/-9.8, median = 4, rang e= 2.4-42.3), including 9 BiVAD and 26 single VAD in patients with functionally univentricular heart. In patients with CHD, duration of VAD support [days]: mean = 144, median = 142, range = 4-422. Of 35 patients with CHD, 24 underwent heart transplantation, 9 died on VAD, and 2 are still on VAD. One-year survival was 89.8% (95% CI=79.4-100%) in patients with AHD and 70.5% (95% CI=56.6-87.7%) in patients with CHD, p=0.023. Five-year survival was 85.0% (95% CI=72.3-100%) in patients with AHD and 65.8% (95% CI=50.9-85.0%) in patients with CHD, p=0.042. Figure 1 documents the longitudinal Kaplan-Meier survival. Conclusion: Berlin Heart VAD facilitates bridge to transplantation in neo- nates, infants, and children with both CHD and AHD, including those with functionally univentricular circulation. Potential etiologies for increased risk in patients with CHD include prior cardiac surgery, complex anatomy, immunosensitization, and associated multisystem comorbidities. (1218) WITHDRAWN (1219) Interdisciplinary Patient Management Following a Controller Fault Alarm in Heartware HVAD J. Mulzer, 1 F. Kaufmann, 2 E. Potapov, 2 and D. Eggert-Doktor. 2 1 HTG, German Heart Institute, Berlin, Germany; and the 2 German Heart Center Berlin, Berlin, Germany. Purpose: The Medtronic Corporation announced that the Heartware HVAD TM will be removed from the global market for new implants as of June 3, 2021. Even after the official recall optimal care of the estimated 4000 patients worldwide is essential. In light of the past events where the new controller failed to start after a controller exchange, we must now focus on developing an optimal concept for this scenario. Methods: Hence, we developed an algorithm to address the optimal patient management following a controller fault alarm in Heartware HVAD including two possible strategies for replacing the Medtronic HVAD with an Abbott HeartMate3 Results: Between 06 and 10/2021 out of 215 ongoing HVAD patients 15 of them (5 female,10 male, median support time of 1815 (IQR:1156- 4007) days) contacted our VAD team regarding a controller fault alarm . In 10 patients the controller exchange following the algorithm was uneventful, in three cases minor bleeding events occurred. Two patients refused hospital admission and the exchange was performed at home with supervision via phone. Conclusion: Even after the official recall of the Heartware HVAD, optimal care of the estimated 4000 patients with this system worldwide is essential. In light of the past events where the new controller failed to start after a controller exchange, we must now focus on developing an optimal concept for this scenario, as all patients will have to undergo a controller exchange in the next years once or even several times if support extends to another time period of more than approximately 4 years owing to the limited life of the internal battery of the HVAD controller. Even if preoperative echo- cardiography produces apparently stable findings, patients may experience rapid deterioration if the system fails, so that cardiovascular support must be established and a subsequent exchange of the HVAD to HM3 per- formed without delay. For patients with absolute contraindication of a pump stop like a thrombosed aortic valve permanently muting the control- ler fault alarm may be discussed. Continuous operation of the pump is not impaired; however the patient will have to be informed and has to acknowledge the constraints of the changed alarm display functionality and a shortened time of power-off alarm capacity. (1220) A Novel Technique for Temporary Right Ventricular Support Using the Existing Cardiopulmonary Bypass Circuit During LVAD Implantation B.M. Wojcik, N.G. Vigneshwar, L.V. Carr, M.S. Mosca, G.A. Justison and J.D. Pal. University of Colorado Hospital, Aurora, CO. Purpose: Right heart failure following implantation of left ventricular assist devices (LVADs) occurs in 9-42% of patients. A variety of predic- tive models allow for selection of patients at high-risk for early RV failure. We sought to develop a technique to provide temporary right heart support using a centrally cannulated cardiopulmonary bypass (CPB) circuit during the LVAD implantation procedure. Methods: Patients at high-risk for RV failure during LVAD implantation were supported by a modified CPB circuit. The objective was to separate from CPB without the need for a percutaneous or durable right ventricular assist device (RVAD). A standard CPB circuit was altered to include three bridges with the ability to exclude the venous reservoir, oxygenator, and arterial filter (Figure 1). Prior to weaning from CPB, a cannula was placed into the main pulmonary artery and connected to the arterial limb. This configuration enabled the circuit to easily transition between standard CPB, a RVAD, or both. Following wean from CPB and reversal of coagul- opathy, the RVAD configuration allowed for delivery of blood while sup- porting the RV. Results: From 2019 to 2021 four patients were identified at a single insti- tution. Pre-operative mean clinical values included central venous pressure (CVP) of 16mmHg § 3.9, pulmonary capillary wedge pressure (PCWP) of S490 The Journal of Heart and Lung Transplantation, Vol 41, No 4S, April 2022